Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Zacks Research upped their Q1 2024 earnings estimates for Alnylam Pharmaceuticals in a research note issued to investors on Wednesday, April 10th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.17) per share for the quarter, up from their previous forecast of ($1.43). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($4.61) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals' Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.05) EPS, Q4 2024 earnings at ($0.88) EPS, FY2024 earnings at ($4.49) EPS, Q1 2025 earnings at ($0.57) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.98) EPS, Q1 2026 earnings at $0.32 EPS and FY2026 earnings at $3.89 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same period in the previous year, the company posted ($1.68) EPS. The firm's revenue for the quarter was up 31.2% on a year-over-year basis.
A number of other analysts have also recently commented on the stock. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, April 5th. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating for the company in a research note on Friday, February 16th. HC Wainwright reiterated a "buy" rating and issued a $395.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Citigroup cut their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a "buy" rating for the company in a research note on Friday, February 16th. Nine investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $216.12.
Get Our Latest Analysis on ALNY
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals stock traded down $3.59 during mid-day trading on Friday, reaching $148.50. The company's stock had a trading volume of 427,819 shares, compared to its average volume of 817,370. The company has a market capitalization of $18.70 billion, a price-to-earnings ratio of -41.71 and a beta of 0.39. Alnylam Pharmaceuticals has a 12 month low of $143.52 and a 12 month high of $218.88. The business's 50 day simple moving average is $153.99 and its 200 day simple moving average is $167.85.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Quent Capital LLC boosted its stake in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 123 shares in the last quarter. KB Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $35,000. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $38,000. GAMMA Investing LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. 92.97% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Stories
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
